Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

The promise and challenges of immune agonist antibody development in cancer.

Mayes PA, Hance KW, Hoos A.

Nat Rev Drug Discov. 2018 Jul;17(7):509-527. doi: 10.1038/nrd.2018.75. Epub 2018 Jun 15. Review.

PMID:
29904196
2.

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.

Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM, Mayes PA, Craigen JL, Rodriguez-Justo M, Yong KL.

Br J Haematol. 2016 Sep;174(6):911-22. doi: 10.1111/bjh.14145. Epub 2016 Jun 17.

PMID:
27313079
3.

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS.

Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9.

4.

1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate.

Bond S, Draffan AG, Fenner JE, Lambert J, Lim CY, Lin B, Luttick A, Mitchell JP, Morton CJ, Nearn RH, Sanford V, Anderson KH, Mayes PA, Tucker SP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):976-81. doi: 10.1016/j.bmcl.2014.11.024. Epub 2014 Nov 14.

PMID:
25595685
5.

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.

Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, Smothers J, Hoos A.

Clin Cancer Res. 2015 Apr 1;21(7):1639-51. doi: 10.1158/1078-0432.CCR-14-2339. Epub 2015 Jan 14.

6.

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC.

Blood. 2014 May 15;123(20):3128-38. doi: 10.1182/blood-2013-10-535088. Epub 2014 Feb 25.

7.

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS.

Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.

8.

ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.

Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, Mayes PA, Wise DR, Thompson CB, Maris JM, Hogarty MD, Simon MC.

Cancer Cell. 2012 Nov 13;22(5):631-44. doi: 10.1016/j.ccr.2012.09.021.

9.

Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.

Mayes PA, Degenhardt YY, Wood A, Toporovskya Y, Diskin SJ, Haglund E, Moy C, Wooster R, Maris JM.

Int J Cancer. 2013 Feb 1;132(3):E149-57. doi: 10.1002/ijc.27781. Epub 2012 Sep 28.

10.

Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation.

Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS.

Sci Transl Med. 2011 Jun 8;3(86):86ra50. doi: 10.1126/scitranslmed.3001384.

11.

Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.

Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, El-Deiry WS.

Cancer Res. 2011 Aug 1;71(15):5265-75. doi: 10.1158/0008-5472.CAN-11-1383. Epub 2011 Jun 6.

12.

FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.

Katz SI, Zhou L, Ferrara TA, Wang W, Mayes PA, Smith CD, El-Deiry WS.

Int J Oncol. 2011 Jul;39(1):91-100. doi: 10.3892/ijo.2011.1019. Epub 2011 Apr 29.

PMID:
21537838
13.

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.

Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, Laudenslager M, Wood AC, Mayes PA, Jagannathan J, Winter C, Mosse YP, Maris JM.

Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3336-41. doi: 10.1073/pnas.1012351108. Epub 2011 Feb 2.

14.

The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine.

Liu HB, Mayes PA, Perlmutter P, McKendrick JJ, Dear AE.

Int J Oncol. 2011 May;38(5):1421-5. doi: 10.3892/ijo.2011.914. Epub 2011 Jan 20.

PMID:
21253674
15.

Integrative genomics identifies LMO1 as a neuroblastoma oncogene.

Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, Schnepp RW, Diamond M, Bosse K, Mayes PA, Glessner J, Kim C, Frackelton E, Garris M, Wang Q, Glaberson W, Chiavacci R, Nguyen L, Jagannathan J, Saeki N, Sasaki H, Grant SF, Iolascon A, Mosse YP, Cole KA, Li H, Devoto M, McGrady PW, London WB, Capasso M, Rahman N, Hakonarson H, Maris JM.

Nature. 2011 Jan 13;469(7329):216-20. doi: 10.1038/nature09609. Epub 2010 Dec 1.

16.

Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.

Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, Maris JM, Simon MC.

Cancer Res. 2010 Dec 15;70(24):10351-61. doi: 10.1158/0008-5472.CAN-10-0740. Epub 2010 Oct 20.

17.
18.

Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target.

Balamuth NJ, Wood A, Wang Q, Jagannathan J, Mayes P, Zhang Z, Chen Z, Rappaport E, Courtright J, Pawel B, Weber B, Wooster R, Sekyere EO, Marshall GM, Maris JM.

Cancer Res. 2010 Apr 1;70(7):2749-58. doi: 10.1158/0008-5472.CAN-09-3844. Epub 2010 Mar 16.

19.

Professional development for night shift nurses.

Mayes P, Schott-Baer D.

J Contin Educ Nurs. 2010 Jan;41(1):17-22; quiz 23-4. doi: 10.3928/00220124-20091222-05. Review.

PMID:
20102138
20.

TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death.

Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS.

Cancer Biol Ther. 2008 Dec;7(12):2034-8.

PMID:
19106633
21.

Noninvasive vascular imaging in fluorescent tumors using multispectral unmixing.

Mayes P, Dicker D, Liu Y, El-Deiry W.

Biotechniques. 2008 Oct;45(4):459-60, 461-4. doi: 10.2144/000112946.

22.

Conformational analogues of Oxamflatin as histone deacetylase inhibitors.

Dear AE, Liu HB, Mayes PA, Perlmutter P.

Org Biomol Chem. 2006 Oct 21;4(20):3778-84. Epub 2006 Aug 31.

PMID:
17024284
23.

The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells.

Mayes PA, El-Deiry WS.

Cancer J. 2006 Jul-Aug;12(4):247-9. No abstract available.

PMID:
16925967
24.

What are caspases 3 and 7 doing upstream of the mitochondria?

Kuribayashi K, Mayes PA, El-Deiry WS.

Cancer Biol Ther. 2006 Jul;5(7):763-5. Epub 2006 Jul 26. Review.

PMID:
16921264
25.

Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment.

Mayes PA, Campbell L, Ricci MS, Plastaras JP, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2005 Oct;4(10):1068-74. Epub 2005 Oct 18.

PMID:
16294025
26.

Toll-like receptor 2 modulates the proinflammatory milieu in Staphylococcus aureus-induced brain abscess.

Kielian T, Haney A, Mayes PM, Garg S, Esen N.

Infect Immun. 2005 Nov;73(11):7428-35.

28.
29.

The type of dietary fat alters the hepatic uptake and biliary excretion of cholesterol from chylomicron remnants.

Lambert MS, Avella MA, Botham KM, Mayes PA.

Br J Nutr. 2000 Apr;83(4):431-8.

PMID:
10858701
30.
31.

Comparison of the effects of palm oil- and butter fat-supplemented diets on the hepatic uptake and metabolism of chylomicron remnants.

Lambert MS, Avella MA, Botham KM, Mayes PA.

Biochem Soc Trans. 1997 Nov;25(4):S685. No abstract available.

PMID:
9450112
32.

Comparison of the uptake and processing of cholesterol from chylomicrons of different fatty acid composition in rats fed high-fat and low-fat diets.

Bravo E, Flora L, Cantafora A, De Luca V, Tripodi M, Avella M, Mayes PA, Botham KM.

Eur J Biochem. 1997 May 15;246(1):92-102.

33.
34.

Molecular processing of HDL by the liver during reverse cholesterol transport.

Mayes PA, Mindham MA.

Z Gastroenterol. 1996 Jun;34 Suppl 3:147-8.

PMID:
8767494
35.
36.

Comparison of the hepatic uptake and processing of cholesterol from chylomicrons of different fatty acid composition in the rat in vivo.

Bravo E, Ortu G, Cantafora A, Lambert MS, Avella M, Mayes PA, Botham KM.

Biochim Biophys Acta. 1995 Oct 5;1258(3):328-36.

PMID:
7548204
37.
38.

Comparison of the lipolysis of chylomicron remnants derived from corn oil or olive oil by hepatic lipase in vitro.

Botham KM, Mayes PA, Avella M, Cantafora A, Bravo E.

Biochem Soc Trans. 1995 May;23(2):284S. No abstract available.

PMID:
7672310
39.

Metabolism of apolipoprotein A-I by the rat kidney.

Mindham MA, Mayes PA.

Biochem Soc Trans. 1995 Feb;23(1):135S. No abstract available.

PMID:
7758700
40.

Supplementation of the diet with corn or olive oil enhances the hepatic metabolism of chylomicron remnants.

Lambert MS, Botham KM, Mayes PA.

Biochem Soc Trans. 1995 Feb;23(1):134S. No abstract available.

PMID:
7758699
41.

Application of organ perfusion to the study of reverse cholesterol transport.

Mindham MA, Mayes PA.

Ann N Y Acad Sci. 1995 Jan 17;748:240-62; discussion 263. No abstract available.

PMID:
7695169
42.

Evaluation in vivo of the differential uptake and processing of high-density lipoprotein unesterified cholesterol and cholesteryl ester in the rat.

Bravo E, Botham KM, Mindham MA, Mayes PA, Marinelli T, Cantafora A.

Biochim Biophys Acta. 1994 Nov 17;1215(1-2):93-102.

PMID:
7948014
43.

Decreased hepatic uptake and processing of high density lipoprotein unesterified cholesterol and cholesteryl ester with age in the rat.

Bravo E, Botham KM, Mindham MA, Mayes PA, Marinelli T, Cantafora A.

J Biochem. 1994 Nov;116(5):1088-95.

44.
45.

Comparison of the hepatic metabolism of chylomicron remnants derived from corn oil or butter fat.

Lambert MS, Botham KM, Mayes PA.

Biochem Soc Trans. 1994 May;22(2):108S. No abstract available.

PMID:
7958179
46.

Differential hepatic uptake of [35S]-labelled HDL apolipoproteins in a dual rat spleen-liver perfusion system.

Mindham MA, Mayes PA.

Biochem Soc Trans. 1994 May;22(2):107S. No abstract available.

PMID:
7958178
47.

Intermediary metabolism of fructose.

Mayes PA.

Am J Clin Nutr. 1993 Nov;58(5 Suppl):754S-765S. doi: 10.1093/ajcn/58.5.754S. Review.

PMID:
8213607
48.

The utilisation of esterified and unesterified cholesterol derived from chylomicron remnants and high density lipoprotein for bile acid synthesis.

Bravo E, Cantafora A, Guldur T, Mindham MA, Mayes PA, Botham KM.

Biochem Soc Trans. 1993 Nov;21(4):459S. No abstract available.

PMID:
8132027
49.

The effect of cyclic AMP analogues on cholesterol metabolism in cultured rat hepatocytes.

Martinez MJ, Lambert MS, Mayes PA, Cho-Chung YS, Botham KM, Ochoa B.

Biochem Soc Trans. 1993 Nov;21(4):458S. No abstract available.

PMID:
8132026
50.

Reverse cholesterol transport from the perfused spleen in the presence or absence of a perfused liver.

Mindham MA, Mayes PA.

Biochem Soc Trans. 1993 May;21(2):146S. No abstract available.

PMID:
8359400

Supplemental Content

Support Center